<DOC>
	<DOCNO>NCT00670839</DOCNO>
	<brief_summary>HIV infect patient expose Hepatitis B virus susceptible develop chronic severe liver disease , major risk cirrhosis liver cancer . However , immune response standard Hepatitis B vaccination decrease HIV-infected patient , compare non HIV-infected individual , , case response , durability carefully follow . This study compare efficacy two strategy revaccination HIV-infected patient n't respond previous hepatitis B vaccination . Failure define two condition : non response primary immunization ( 2 4 single-dose injection receive screen visit ) failure single 20 µg boost include study .</brief_summary>
	<brief_title>Trial Comparing Two Strategies Vaccination Against Hepatitis B HIV-infected Patients Non Responding Primary Immunization ( B-BOOST )</brief_title>
	<detailed_description>Comparison 2 revaccination strategy randomize HIV-infected patient T CD4 cell count 200/mm3 Intervention : 1 . Arm A : GenHevac-B® 20μg IM M0 , M1 , M6 2 . Arm B : GenHevac-B® 40μg IM M0 , M1 , M6</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HIV1 infection T CD4 cell count number 200 /mm3 History 2 4 injection Hepatitis B vaccine , time past No history Hepatitis B vaccination doubledose schedule No response Hepatitis B vaccination : serology Hepatitis B negative ( AgHBs , AbHBs AbHBc negative ) previous twelve month screen visit AbHBs titers 10 IU/ml four week boost GenhevacB® 20μg precede randomization unchanged ARV treatment last 2 month patient receive ARV screen visit Undetectable HIV RNA last 6 month ongoing ARV patient T CD4 cell level 350/mm3 HIV1 plasma load 100 000 copy per ml patient without ARV Negative pregnancy test screen visit , immediately GenhevacB® 20 µg boost injection precede randomization Acute cytolysis last 3 month transaminases equal 5 time upper limit normal HIVHCV coinfected patient , transaminase equal 2 time upper limit normal non coinfected patient Any vaccine receive month precede inclusion History hypersensitivity component GenHevacB acute opportunistic infection treat month screen visit Severe acute pyretic infection unexplained fever week inclusion Hemopathy solidorgan cancer Prothrombin factor equal 50 % and/or platelet equal 50 000 per mm3 Immunosuppressive treatment general corticotherapy ( equal 0,5 mg per kg per day least 7 day ) last 6 month screen visit Immunomodulating treatment ( interferon , interleukine2 , … ) last 6 month screen visit Splenectomy Decompensated cirrhosis ( Child Pugh B C ) Renal failure ( creatinine clearance 50 ml/mn ) Other severe immunocompromised condition relate HIV infection ( solidorgan transplantation , chemotherapy last 6 month , … . ) Any participation another clinical trial plan Week 28</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hepatitis B vaccination</keyword>
	<keyword>GenHevac-B Pasteur</keyword>
	<keyword>HIV infection</keyword>
</DOC>